179 related articles for article (PubMed ID: 12548358)
1. Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease.
Morgante L; Epifanio A; Spina E; Di Rosa AE; Zappia M; Basile G; La Spina P; Quattrone A
Neurol Sci; 2002 Sep; 23 Suppl 2():S89-90. PubMed ID: 12548358
[TBL] [Abstract][Full Text] [Related]
2. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis.
Morgante L; Epifanio A; Spina E; Zappia M; Di Rosa AE; Marconi R; Basile G; Di Raimondo G; La Spina P; Quattrone A
Clin Neuropharmacol; 2004; 27(4):153-6. PubMed ID: 15319699
[TBL] [Abstract][Full Text] [Related]
3. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia.
Reddy S; Factor SA; Molho ES; Feustel PJ
Mov Disord; 2002 Jul; 17(4):676-81. PubMed ID: 12210856
[TBL] [Abstract][Full Text] [Related]
4. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis.
Merims D; Balas M; Peretz C; Shabtai H; Giladi N
Clin Neuropharmacol; 2006; 29(6):331-7. PubMed ID: 17095896
[TBL] [Abstract][Full Text] [Related]
5. [Effects of quetiapine at low doses on psychosis motor disability and stress of the caregiver in patients with Parkinson's disease].
Giménez-Roldán S; Navarro E; Mateo D
Rev Neurol; 2003 Mar 1-15; 36(5):401-4. PubMed ID: 12640589
[TBL] [Abstract][Full Text] [Related]
6. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.
Ondo WG; Tintner R; Voung KD; Lai D; Ringholz G
Mov Disord; 2005 Aug; 20(8):958-63. PubMed ID: 15800937
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis.
Klein C; Prokhorov T; Miniovich A; Dobronevsky E; Rabey JM
Clin Neuropharmacol; 2006; 29(4):215-9. PubMed ID: 16855423
[TBL] [Abstract][Full Text] [Related]
8. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease.
Juncos JL; Roberts VJ; Evatt ML; Jewart RD; Wood CD; Potter LS; Jou HC; Yeung PP
Mov Disord; 2004 Jan; 19(1):29-35. PubMed ID: 14743357
[TBL] [Abstract][Full Text] [Related]
9. Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease.
Fernandez HH; Trieschmann ME; Okun MS
Mov Disord; 2005 Jan; 20(1):104-5. PubMed ID: 15390047
[TBL] [Abstract][Full Text] [Related]
10. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration.
Rabey JM; Prokhorov T; Miniovitz A; Dobronevsky E; Klein C
Mov Disord; 2007 Feb; 22(3):313-8. PubMed ID: 17034006
[TBL] [Abstract][Full Text] [Related]
11. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease.
Fernandez HH; Friedman JH; Jacques C; Rosenfeld M
Mov Disord; 1999 May; 14(3):484-7. PubMed ID: 10348474
[TBL] [Abstract][Full Text] [Related]
12. [Effect of quetiapine fumarate on drug-induced psychosis in patients with Parkinson's disease].
Kohmoto J; Kihira T; Miwa H; Kondo T
No To Shinkei; 2002 Jun; 54(6):489-92. PubMed ID: 12166098
[TBL] [Abstract][Full Text] [Related]
13. Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years.
Berger GE; Proffitt TM; McConchie M; Kerr M; Markulev C; Yuen HP; O'Donnell C; Lubman D; Polari A; Wood S; Amminger PG; McGorry PD
J Clin Psychiatry; 2008 Nov; 69(11):1702-14. PubMed ID: 19036233
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of quetiapine for treatment of geriatric psychosis.
Yang CH; Tsai SJ; Hwang JP
J Psychopharmacol; 2005 Nov; 19(6):661-6. PubMed ID: 16272189
[TBL] [Abstract][Full Text] [Related]
15. Akathisia as a side effect of antipsychotic treatment with quetiapine in a patient with Parkinson's disease.
Prueter C; Habermeyer B; Norra C; Kosinski CM
Mov Disord; 2003 Jun; 18(6):712-3. PubMed ID: 12784279
[TBL] [Abstract][Full Text] [Related]
16. [Value of clozapine in treatment of psychotic disorder in Parkinson disease].
Abbar M; Courtet P; Castelnau D
Encephale; 1996; 22(1):53-63. PubMed ID: 8681876
[TBL] [Abstract][Full Text] [Related]
17. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial.
Pintor L; Valldeoriola F; Baillés E; Martí MJ; Muñiz A; Tolosa E
Clin Neuropharmacol; 2012; 35(2):61-6. PubMed ID: 22388466
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients.
Fernandez HH; Trieschmann ME; Burke MA; Jacques C; Friedman JH
Mov Disord; 2003 May; 18(5):510-4. PubMed ID: 12722164
[TBL] [Abstract][Full Text] [Related]
19. Clozapine treatment of psychosis in patients with Parkinson's disease.
Friedman JH
J Clin Psychiatry; 1994 Feb; 55(2):79. PubMed ID: 8077160
[No Abstract] [Full Text] [Related]
20. Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing.
Schindehütte J; Trenkwalder C
Clin Neurol Neurosurg; 2007 Feb; 109(2):188-91. PubMed ID: 16949733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
